Nothing to sneeze at: Histamine and histamine receptors in oral carcinogenesis
- PMID: 32395857
- DOI: 10.1111/odi.13411
Nothing to sneeze at: Histamine and histamine receptors in oral carcinogenesis
Abstract
Oral squamous cell carcinoma (OSCC), the most common oral malignancy, shows an increasing rate of incidence worldwide. In spite of the recent advances in cancer research, OSCC therapy continues to have unfavourable outcomes, and thus, patient's prognosis remains relatively poor. Current research has been devoted to identifying novel therapeutic targets also in the tumour microenvironment (TME). Histamine and its G-protein-coupled receptors (H1R-H4R) play vital roles in multiple cancer-associated processes in TME, where histamine is mainly produced by mast cells. However, oral epithelial cells were recently shown to produce low concentrations of histamine in autocrine and paracrine modes. These findings, together with the discovery of the high-affinity histamine H4 receptor, have led to a massive increase in our understanding of histamine functions. In this review, we aim to summarize the most recent findings regarding histamine and its receptors and their involvement in oral carcinogenesis-from oral potentially malignant disorders (OPMDs) to invasive OSCC. Importantly, histamine receptors are differentially expressed in OPMDs and OSCC. Furthermore, H1R and H4R are associated with clinicopathological characteristics of OSCC patients, suggesting a role in prognosis. Due to the enormous success of histamine-based medications, histamine receptors may also represent promising and viable drug targets in oral cancer.
Keywords: epithelial dysplasia; histamine; histamine receptors; mast cells; oral lichen planus; oral squamous cell carcinoma.
© 2020 The Authors. Oral Diseases published by John Wiley & Sons Ltd.
References
REFERENCES
-
- Akdis, C. A., & Simons, F. E. (2006). Histamine receptors are hot in immunopharmacology. European Journal of Pharmacology, 533(1-3), 69-76. https://doi.org/10.1016/j.ejphar.2005.12.044
-
- Almahmoudi, R., Salem, A., Sieviläinen, M., Sundquist, E., Almangush, A., Toppila-Salmi, S., … Al-Samadi, A. (2018). Extracellular interleukin-17F has a protective effect in oral tongue squamous cell carcinoma. Head and Neck, 40(10), 2155-2165. https://doi.org/10.1002/hed.25207
-
- Ankle, M. R., Kale, A. D., & Nayak, R. (2007). Mast cells are increased in leukoplakia, oral submucous fibrosis, oral lichen planus and oral squamous cell carcinoma. Journal of Oral and Maxillofacial Pathology, 11, 18-22. https://doi.org/10.4103/0973-029X.33959
-
- Apolone, G., Joppi, R., Bertele', V., & Garattini, S. (2005). Ten years of marketing approvals of anticancer drugs in Europe: Regulatory policy and guidance documents need to find a balance between different pressures. British Journal of Cancer, 93(5), 504-509. https://doi.org/10.1038/sj.bjc.6602750
-
- Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 68(6), 394-424. https://doi.org/10.3322/caac.21492
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical